Skip to search formSkip to main contentSkip to account menu

100 ML eptifibatide 0.75 MG/ML Injection [Integrilin]

Known as: INTEGRILIN 75 MG in 100 ML Injection, 100 ML Integrilin 0.75 MG/ML Injection, Eptifibatide 0.75 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Integrilin] 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (1)

100 ML eptifibatide 0.75 MG/ML Injection
InjectionIntegrilinSodium Hydroxidecitric acid monohydrate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
RGD-Modified Nano-Liposomes Encapsulated Eptifibatide with Proper Hemocompatibility and Cytotoxicity Effect
Background Eptifibatide (Integrilin®) is a hepta-peptide drug which specifically prevents the aggregation of activated platelets… 
Review
2018
Review
2018
EPTIFIBATIDE-LOADED LIPOSOMES MICROFLUIDIC-BASED LOADING AND SET-UP OF AN HPLC ANALYSIS
BACKGROUND Eptifibatide (Integrilin®) is an intravenous peptide drug that selectively inhibits ligand binding to the platelet… 
2013
2013
Bringing pharmacogenetics to the bedside
Dear Editor, The study ‘Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease… 
Review
2012
Review
2012
Spotlight on Eptifibatide in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention
Eptifibatide (Integrilin®) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist… 
2010
2010
Accident ischémique embolique pendant traitement endovasculaire d’un anévrisme cérébral traité par thrombolyse intraveineuse avec eptifibatide (Integrilin®). À propos d’un cas
2008
2008
Inhibiteurs de ladhésivité plaquettaire. Un aperçu
Les maladies cardiovasculaires athéroscléroti ques sont la cause de décès numéro un en Europe et aux Etats-Unis; aux Etats-Unis… 
2003
2003
Évaluation de l‘utilisation d‘un inhibiteur de la glycoprotéine IIbIIIa, l‘Integrilin ® , dans un service de cardiologie
Les inhibiteurs de la glycoproteine IIbIIIa, en bloquant directement la voie finale commune de l‘agregation plaquettaire… 
2001
2001
Les anti-GPIIb-IIIa
2000
2000
Inhibiteurs des glycoprotéines plaquettaires IIb-IIIa : utilisation clinique et effets physiopathologiques associés
Le complexe GPIIb-IIIa (integrine alphaIIbbeta3) constitue une nouvelle cible pour les medicaments antithrombotiques. En bloquant… 
1999
1999
Eptifibátida INTEGRILIN (SP Europa)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)